Proinflammatory mediators trigger intensive postischemic inflammatory remodeling of the blood-brain barrier (BBB) including extensive brain endothelial cell surface and junctional complex changes. Junctional adhesion molecule-A (JAM-A) is a component of the brain endothelial junctional complex with dual roles: paracellular route occlusion and regulating leukocyte docking and migration. The current study examined the contribution of JAM-A to the regulation of leukocyte (neutrophils and monocytes/macrophages) infiltration and the postischemic inflammatory response in brain ischemia/reperfusion (I/R injury). Brain I/R injury was induced by transient middle cerebral artery occlusion (MCAO) for 30 min in mice followed by reperfusion for 0-5 days, during which time JAM-A antagonist peptide (JAM-Ap) was administered. The peptide, which inhibits JAM-A/ leukocyte interaction by blocking the interaction of the C2 domain of JAM-A with LFA on neutrophils and monocytes/macrophages, attenuated I/R-induced neutrophil and monocyte infiltration into brain parenchyma. Consequently, mice treated with JAM-A peptide during reperfusion had reduced expression (~3-fold) of inflammatory mediators in the ischemic penumbra, reduced infarct size (94 ± 39 vs 211 ± 38 mm 3 ) and significantly improved neurological score. BBB hyperpermeability was also reduced. Collectively, these results indicate that JAM-A has a prominent role in regulating leukocyte infiltration after brain I/R injury and could be a new target in limiting post-ischemic inflammation.
Introduction
Inflammation contributes to secondary brain injury after ischemia. Inflammation initiation and progression involve a complex set of interactions between brain endothelial cells and leukocytes, predominantly neutrophils and monocytes/macrophages, allowing first neutrophils and then monocytes to adhere to endothelial cells, traverse the bloodbrain barrier (BBB) and eventually migrate into the injured brain tissue (Becker, 2001; del Zoppo et al., 1991; Garcia et al., 1994; Jander et al., 2007) . Infiltrating neutrophils and monocytes/macrophages further amplify the inflammatory reaction and exacerbate brain injury (Becker, 2001; Jander et al., 2007) . Post-ischemic inflammation is considered a good target for potential therapy, with a relatively long duration (hours or several days) providing a longer treatment window (Becker, 2001; Garcia et al., 1994; Tuttolomondo et al., 2009) .
Perturbations in BBB integrity, with subsequent increased vascular permeability and leukocyte infiltration, play a pivotal role in postischemic inflammation (Fernandez-Lopez et al., 2012; Liu et al., 2012; Yang and Rosenberg, 2011) . During this process, most tight junction (TJ) complex components, particularly the transmembrane proteins occludin and claudin-5, undergo redistribution from the membrane cell surface (Dimitrijevic et al., 2006; Fernandez-Lopez et al., 2012; Jiao et al., 2011; Liu et al., 2012; Yang and Rosenberg, 2011) . In this way, a paracellular route is opened and leukocyte transmigration enhanced. However, leukocyte migration into brain parenchyma also requires chemotactic signals and close interaction with the brain endothelial lateral surface, where the specific adhesion molecules (e.g. CD31, CD99 and junction adhesion molecules) control leukocyte movement (Mamdouh et al., 2009; Schenkel et al., 2002) .
Junctional adhesion molecules (JAMs) are members of the immunoglobulin superfamily. In general, JAMs are expressed at cell-to-cell junctions in endothelia and epithelia and display different patterns of homotypic and heterotypic adhesion (Martin-Padura et al., 1998;  
